Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised SS0331 in healthy volunteers and patients with chronic airway infections
2025-523875-48-00Phase 2Authorised
- Sponsor
- SoftOx Solutions
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hypochlorous acid in Airways Infection, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and 3 more (2 arms), sponsored by SoftOx Solutions. Primary endpoints: Phase 1 safety and tolerability and Phase 2a antibacterial effect. Planned start Dec 2025; status: authorised.
02
Drugs
hypochlorous acid
03
Conditions
Airways Infectioncystic fibrosis (CF)primary ciliary dyskinesia (PCD)bronchiectasisbacterial airway infections
Beyond the preview
Go deeper on 2025-523875-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523875-48-00.